Current status and progress of the launch of Quizartinib in China

Quizartinib(Quizartinib) is an oral, small molecule kinase inhibitor indicated for the treatment of acute myeloid leukemia (AML), particularly those with FLT3 gene mutations. FLT3 (Fms-like Tyrosine Kinase 3) is a receptor tyrosine kinase that is widely present on hematopoietic stem cells. It plays a crucial role in the proliferation, differentiation and survival of blood cells. Under normal circumstances, the activation of FLT3 receptors is regulated by ligands and helps the proliferation and differentiation of hematopoietic stem cells. However, when the FLT3 gene is mutated, especially internal tandem duplication (ITD) mutations, the FLT3 receptor will be continuously activated, leading to uncontrolled proliferation of leukemia cells and increasing the incidence and mortality of leukemia.

Quizatinib, as a selective inhibitor ofFLT3 receptor, can specifically inhibit this mutation and prevent the abnormal proliferation and survival of leukemia cells, thereby slowing down the development of acute myeloid leukemia. FLT3-ITD mutation is one of the most common molecular abnormalities in acute myeloid leukemia, with approximately 25%-30% of AML patients exhibiting this mutation. Quizartinib has demonstrated significant therapeutic effects in these patients, especially when combined with standard chemotherapy drugs such as cytarabine (Ara-C) and allium ring drugs (such as idarubicin), providing more effective disease control.

In addition to its importance in initial treatment, quizartinib also plays a vital rolein the maintenance treatment of AML. AML patients usually face a high risk of relapse after entering remission after initial chemotherapy. In order to avoid disease recurrence, quizartinib is often used as single-agent maintenance therapy to help patients prolong the remission period and prevent reactivation of the disease. According to clinical trial data, quizartinib can significantly improve patients' overall survival and disease-free survival when used in combination with other chemotherapy drugs.

Keyword tags: Quizartinib, acute myeloid leukemia, FLT3 mutation, chemotherapy, consolidation therapy, maintenance therapy, targeted therapy, treatment effect

Reference materials：https://www.vanflyta.com/en